Alexander Kanevsky
Psychiatry · Jamison, PANPI 1780750299
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 500 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 500 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Lundbeck LLC$1K
- Alkermes, Inc.$709
- Sunovion Pharmaceuticals Inc.$405
- plus $2K from 14 others
What the payments were for
- Food & beverage$8,220100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 90 | $1,735 |
| AbbVie(2 entities) | 149 | $1,618 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 58 | $1,200 |
| Lundbeck LLC | 53 | $1,040 |
| Alkermes, Inc. | 43 | $709 |
| Sunovion Pharmaceuticals Inc. | 24 | $405 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $368 |
| Johnson & Johnson | 12 | $242 |
| Vanda Pharmaceuticals Inc. | 13 | $208 |
| Teva Pharmaceuticals USA, Inc. | 9 | $187 |
| Axsome Therapeutics, Inc. | 7 | $154 |
| Shire North American Group Inc | 7 | $109 |
| Neurocrine Biosciences, Inc. | 4 | $74 |
| Idorsia Pharmaceuticals US Inc | 3 | $53 |
| E.r. Squibb & Sons, L.L.C. | 1 | $26 |
| Almatica Pharma LLC | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Corium, LLC | 1 | $24 |
| Neos Therapeutics, LP | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
How this compares
$8,232 in reported general payments places this provider in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Risperidone | 21 | $519 |
| Mirtazapine | 24 | $496 |
| Quetiapine Fumarate | 26 | $202 |
| Bupropion XlBupropion Hcl | 26 | $188 |
| Aripiprazole | 16 | $147 |
| Duloxetine Hcl | 11 | $131 |
| Gabapentin | 11 | $73 |
| Clonidine Hcl | 14 | $33 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Jamison
- Rebecca RomaPittsburgh$3.3M
- Robert NelsonWyomissing$2.2M
- Matthew BergerMoosic$1.7M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
- Daniel WeintraubPhiladelphia$647K
- Sachin MehtaBlue Bell$646K
- Jane JesseKingston$617K
- Michael ThasePhiladelphia$396K
- Michael KwiatBeaver$390K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.